NASDAQ:SRRA Sierra Oncology (SRRA) Stock Price, News & Analysis → $25,000 into $109,616 in two months? (From WealthPress) (Ad) Free SRRA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$54.99▼$54.9950-Day Range$54.73▼$54.9952-Week Range$14.91▼$55.19VolumeN/AAverage Volume931,731 shsMarket Capitalization$1.34 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Sierra Oncology alerts: Email Address Ad Crypto 101 MediaAltcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… Click here now to register for the event (FOR FREE!) About Sierra Oncology Stock (NASDAQ:SRRA)Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California.Read More Ad Porter & CompanyAI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… Simply click here to read Porter’s warning on The Big AI Die-Up now. SRRA Stock News HeadlinesFebruary 21, 2024 | thestreet.comSierra Oncology Inc.November 9, 2023 | time.comSierra Coupon for OctoberMarch 28, 2024 | Behind the Markets (Ad)Urgent: Protect Your Investments from a Chinese InvasionAn alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.September 18, 2023 | msn.comFDA approves GSK's unique myelofibrosis treatment OjjaaraSeptember 18, 2023 | msn.comPleasant Surprise For GSK: FDA Approves Bone Marrow Cancer Therapy Acquired Via Sierra Oncology DealSeptember 18, 2023 | msn.comFDA approves GSK's Ojjaara for treatment of myelofibrosis-related anaemiaJune 16, 2023 | proactiveinvestors.comAnalyst calls of the week: Palo Alto upped, Carnival earnings preview and moreJune 12, 2023 | fool.comSierra Oncology (NASDAQ: SRRA)March 28, 2024 | Insiders Exposed (Ad)This consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.February 25, 2023 | benzinga.comCelyad Oncology Stock (NASDAQ:CYAD), Quotes and News SummaryFebruary 22, 2023 | bbc.co.ukSierra LeoneJanuary 20, 2023 | finance.yahoo.comInterventional Oncology Global Market - Forecast To 2029January 5, 2023 | nasdaq.comGSK Signs Deal to Develop Antibodies for Treating CancerOctober 12, 2022 | marketwatch.comSareum Holdings Says Sierra Oncology To Return Cancer Treatment License; Shares FallSeptember 25, 2022 | marketwatch.comCompanion Diagnostic Tests in Oncology Market 2022 Key Product Segments, Application Analysis, and Industry Growth Forecast by 2027September 1, 2022 | thestreet.com15 Biotech Firms That Have Strong Potential to Be Acquired: JefferiesAugust 8, 2022 | yahoo.comSierra Leone passes new laws to boost landowners' rightsJuly 4, 2022 | marketwatch.comSareum Holdings Says GSK Completes Acquisition of Sierra OncologyJune 17, 2022 | finance.yahoo.comSierra Oncology Announces Submission of New Drug Application for Momelotinib to US Food & Drug AdministrationJune 13, 2022 | uk.finance.yahoo.comSierra Oncology hits 52w high – but will it continue?May 26, 2022 | finance.yahoo.comMomelotinib Pivotal Phase 3 Data Receives Oral Presentation at American Society of Clinical Oncology Annual MeetingMay 12, 2022 | finance.yahoo.comSierra Oncology Announces Oral Presentation of Momelotinib Pivotal Phase 3 Data at European Hematology Association Annual MeetingMay 6, 2022 | finance.yahoo.comSierra Oncology Reports First Quarter 2022 ResultsMay 2, 2022 | stockhouse.comSIERRA ONCOLOGY INVESTOR ALERT - Kuznicki Law PLLC Investigates Proposed Sale of Sierra Oncology, Inc - SRRAApril 14, 2022 | msn.comBiotech Stock Roundup: SRRA Surges on GSK Buyout, HALO Offers Update & MoreApril 14, 2022 | msn.comAnalyzing Sierra Oncology Inc's Short InterestApril 14, 2022 | markets.businessinsider.comAnalyst Ratings for Sierra OncologySee More Headlines Receive SRRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sierra Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/05/2021Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:SRRA Previous SymbolNASDAQ:DNAI CUSIPN/A CIK1290149 Webwww.sierraoncology.com Phone(604) 558-6536FaxN/AEmployees109Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($6.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-94,660,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-111.88% Return on Assets-100.01% Debt Debt-to-Equity Ratio0.02 Current Ratio21.27 Quick Ratio21.27 Sales & Book Value Annual Sales$300,000.00 Price / Sales4,476.00 Cash FlowN/A Price / Cash FlowN/A Book Value$6.16 per share Price / Book8.93Miscellaneous Outstanding Shares24,419,000Free Float13,650,000Market Cap$1.34 billion OptionableOptionable Beta0.03 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Stephen George Dilly M.B.B.S (Age 62)Pres, CEO & Director Comp: $1.02MMr. Sukhi Jagpal CPA (Age 48)CA, CBV, CPA, M.B.A., MBA, Chief Financial Officer Comp: $648.02kDr. Barbara J. Klencke M.D. (Age 65)Chief Medical Officer Comp: $773.39kMs. Christina Thomson J.D. (Age 51)M.S., Gen. Counsel, Chief Compliance Officer & Sec. Mr. William D. Turner (Age 56)Chief Regulatory & Technical Operations Officer Mr. Kevin Norrett M.B.A. (Age 49)M.S., Chief Bus. Officer More ExecutivesKey CompetitorsAbCellera BiologicsNASDAQ:ABCLProthenaNASDAQ:PRTADay One BiopharmaceuticalsNASDAQ:DAWNMannKindNASDAQ:MNKDPacira BioSciencesNASDAQ:PCRXView All Competitors SRRA Stock Analysis - Frequently Asked Questions How were Sierra Oncology's earnings last quarter? Sierra Oncology, Inc. (NASDAQ:SRRA) announced its earnings results on Friday, November, 5th. The biotechnology company reported ($2.10) EPS for the quarter, missing the consensus estimate of ($1.78) by $0.32. What other stocks do shareholders of Sierra Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sierra Oncology investors own include VBI Vaccines (VBIV), T2 Biosystems (TTOO), Co-Diagnostics (CODX), Tonix Pharmaceuticals (TNXP), Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX), Actinium Pharmaceuticals (ATNM), OPKO Health (OPK), Sorrento Therapeutics (SRNE) and Biocept (BIOC). This page (NASDAQ:SRRA) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford ClubFed launches fourth dollar overhaulStansberry ResearchSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sierra Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.